BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 7, 2026
Home » Topics » Clinical

Clinical
Clinical RSS Feed RSS

Chinatrials

Chinatrials highlights the trials and tribulations of running studies now

Oct. 22, 2020
By Elise Mak
The Chinatrials roundtable went virtual this year and drew clinical trial experts to discuss state-of-the-art clinical trial design strategies, which are increasingly important in a more competitive clinical landscape.
Read More

In the clinic for Oct. 22, 2020

Oct. 22, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Alnylam, Ardelyx, Aslan, Daiichi, Dicerna, Enlivex, Fibrogen, Galera, Genmab, Horizon, Immunitybio, Medicinova, Mesoblast, Moderna, Nantkwest, Omeros, Soligenix, Trippbio.
Read More

Crispr posts solid early stage allogeneic CAR T data marred by a death in the study

Oct. 21, 2020
By Brian Orelli
Crispr Therapeutics AG's first stab at developing an allogeneic CAR T-cell therapy, CTX-110, looks promising, but the efficacy data were overshadowed by a death in the study.
Read More

Australia’s Actinogen advances lead compound Xanamem in Alzheimer’s disease, fragile X syndrome

Oct. 21, 2020
By Tamra Sami
PERTH, Australia – Sydney-based Actinogen Medical Ltd. will advance its lead compound, Xanamem, into two proof-of-concept phase II studies in Alzheimer’s disease and fragile X syndrome.
Read More

In the clinic for Oct. 21, 2020

Oct. 21, 2020
Clinical updates, including trial initiations, enrollment status and data readouts and publications: AB Science, Affinivax, Biogen, Briacell, Cidara, Crispr, Gilead, Mycovia, Myovant, Onxeo, Pfizer, Trevi, Vir.
Read More
Hospital patient wearing pulse oximeter

As WHO findings disappoint, COVID-19 developers stand in Solidarity

Oct. 20, 2020
By Randy Osborne
The large-scale failure of a handful of drugs repurposed for COVID-19 hasn’t slowed efforts to find existing – and new – therapies as well as vaccines that can fight the pandemic, with research updates continuing to roll out.
Read More

Second inactivated SARS-CoV-2 vaccine candidate from China reports clinical data

Oct. 20, 2020
By Cormac Sheridan
DUBLIN – The Lancet Infectious Diseases has published the first clinical data on BBIBP-CorV, an inactivated whole virus vaccine directed against SARS-CoV-2. The early stage phase I/II study tested the Chinese-developed vaccine in 540 healthy volunteers, including 96 older participants.
Read More
Antibodies attacking SARS-CoV-2 virus

COVID-19 challenge study to start in the U.K. next year

Oct. 20, 2020
By Nuala Moran
LONDON – The world’s first COVID-19 human challenge trial is due to start in London next year, after the government announced £33.6 million (US$43.5 million) funding for the project.
Read More
Intellis system with tablet app

Study shows sustained back pain relief with DTM SCS therapy using Intellis

Oct. 20, 2020
By Meg Bryant
Medtronic plc reported 12-month data from a large, multicenter, randomized controlled clinical trial affirming the superiority of differential target multiplexed spinal cord stimulation (DTM SCS) in relieving chronic back pain, vs. traditional SCS therapy, using its Intellis platform.
Read More

Redeeming qualities in PTSD phase II – for Aptinyx shares, too

Oct. 20, 2020
By Randy Osborne
Aptinyx Inc. CEO Norbert Riedel said the design is unclear of the pivotal trial due next year with the N-methyl-D-aspartate (NMDA) receptor modulator NYX-783 in post-traumatic stress disorder (PTSD), as fine points must be hashed out with the FDA.
Read More
Previous 1 2 … 361 362 363 364 365 366 367 368 369 … 450 451 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • Dividing cancer cells in the cross hairs

    SKL-35501 shows broad antitumor activity in solid tumors

    BioWorld Science
    Neurotensin receptor 1 (NTSR1) is overexpressed in several aggressive solid tumors, including colorectal and pancreatic cancer, making it a promising therapeutic...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing